Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
2.

Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations.

Laut KG, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, Radoi R, Schmied B, Chkhartishvili N, Florence E, Ristola M, Fätkenheuer G, Mulcahy F, Schmid P, Kuzovatova E, Paduta D, Smidt J, Domingo P, Szlávik J, Lundgren J, Mocroft A, Kirk O; EuroSIDA study group.

AIDS. 2018 Nov 28;32(18):2807-2819. doi: 10.1097/QAD.0000000000002035.

PMID:
30289816
3.

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.

Peters L, Laut K, Resnati C, Del Campo S, Leen C, Falconer K, Trofimova T, Paduta D, Gatell J, Rauch A, Lacombe K, Domingo P, Chkhartishvili N, Zangerle R, Matulionyte R, Mitsura V, Benfield T, Zilmer K, Khromova I, Lundgren J, Rockstroh J, Mocroft A; EuroSIDA Study Group.

AIDS. 2018 Sep 10;32(14):1995-2004. doi: 10.1097/QAD.0000000000001928.

4.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
5.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

6.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.

Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group.

AIDS. 2012 Jan 28;26(3):315-23. doi: 10.1097/QAD.0b013e32834e8805.

PMID:
22112597
7.

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group.

J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

PMID:
21844300
8.

Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.

Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group.

AIDS. 2011 Jul 31;25(12):1505-13. doi: 10.1097/QAD.0b013e328348fafd.

PMID:
21610489
9.

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.

Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group.

AIDS. 2011 Jun 19;25(10):1305-15. doi: 10.1097/QAD.0b013e328347f6f7.

PMID:
21522006
10.

A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.

Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group.

HIV Clin Trials. 2011 Mar-Apr;12(2):109-17. doi: 10.1310/hct1202-109.

PMID:
21498154
11.

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.

Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31.

12.

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70. doi: 10.1097/QAI.0b013e3181e9be6b.

PMID:
20700060
13.

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.

Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group.

Cancer. 2010 Nov 15;116(22):5306-15. doi: 10.1002/cncr.25311.

14.

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.

Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2010;15(4):563-70. doi: 10.3851/IMP1559.

PMID:
20587849
15.

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group.

AIDS. 2010 Jul 17;24(11):1667-78. doi: 10.1097/QAD.0b013e328339fe53.

PMID:
20523203
16.

History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.

Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group.

HIV Med. 2010 Aug;11(7):469-78. doi: 10.1111/j.1468-1293.2009.00816.x. Epub 2010 Feb 22.

17.

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.

J Infect Dis. 2009 Sep 1;200(5):687-97. doi: 10.1086/604731.

PMID:
19604043
18.

Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.

PMID:
19360931
19.

Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.

van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group.

Antivir Ther. 2009;14(1):75-83.

PMID:
19320239
20.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group.

AIDS. 2008 Nov 12;22(17):2381-90. doi: 10.1097/QAD.0b013e328317a6eb.

PMID:
18981778

Supplemental Content

Loading ...
Support Center